Rocket Pharmaceuticals Boeing Bond
RCKT Stock | USD 14.39 0.19 1.34% |
Rocket Pharmaceuticals holds a debt-to-equity ratio of 0.057. At this time, Rocket Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year. Long Term Debt Total is likely to gain to about 35.2 M in 2024, whereas Long Term Debt is likely to drop slightly above 35 M in 2024. . Rocket Pharmaceuticals' financial risk is the risk to Rocket Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Rocket Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Rocket Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Rocket Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Rocket Pharmaceuticals' stakeholders.
For most companies, including Rocket Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Rocket Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Rocket Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 3.9778 | Book Value 3.619 | Return On Assets (0.34) | Return On Equity (0.59) |
Rocket |
Given the importance of Rocket Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of Rocket Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Rocket Pharmaceuticals to issue bonds at a reasonable cost.
Popular Name | Rocket Pharmaceuticals Boeing Co 2196 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US77313F1066 |
Bond Issue ISIN Code | US097023DG73 |
S&P Rating | Others |
Maturity Date | 4th of February 2026 |
Issuance Date | 4th of February 2021 |
Coupon | 2.196 % |
Rocket Pharmaceuticals Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
US77314EAA64 | US77314EAA64 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
US77310VAA26 | US77310VAA26 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
US77313LAA17 | US77313LAA17 | Details | |
US77313LAB99 | US77313LAB99 | Details |
Understaning Rocket Pharmaceuticals Use of Financial Leverage
Rocket Pharmaceuticals' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Rocket Pharmaceuticals' current equity. If creditors own a majority of Rocket Pharmaceuticals' assets, the company is considered highly leveraged. Understanding the composition and structure of Rocket Pharmaceuticals' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 25 M | 30.8 M | |
Net Debt | -30.9 M | -32.4 M | |
Short Term Debt | 5.4 M | 3.5 M | |
Long Term Debt | 40.3 M | 35 M | |
Short and Long Term Debt | 4.4 M | 2.7 M | |
Long Term Debt Total | 31.6 M | 35.2 M | |
Net Debt To EBITDA | 0.13 | 0.12 | |
Debt To Equity | 0.05 | 0.05 | |
Interest Debt Per Share | 0.32 | 0.30 | |
Debt To Assets | 0.04 | 0.04 | |
Long Term Debt To Capitalization | 0.04 | 0.04 | |
Total Debt To Capitalization | 0.05 | 0.07 | |
Debt Equity Ratio | 0.05 | 0.05 | |
Debt Ratio | 0.04 | 0.04 | |
Cash Flow To Debt Ratio | (7.78) | (7.39) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.